Advertisement
Advertisement
U.S. Markets closed
Advertisement
Advertisement
Advertisement
Advertisement

Bluejay Diagnostics, Inc. (BJDX)

NasdaqCM - NasdaqCM Real Time Price. Currency in USD
0.6501-0.0499 (-7.13%)
At close: 04:00PM EST
0.6827 +0.03 (+5.01%)
After hours: 05:28PM EST
Advertisement
Full screen
Trade prices are not sourced from all markets
Gain actionable insight from technical analysis on financial instruments, to help optimize your trading strategies
Chart Events
Neutralpattern detected
Previous Close0.7000
Open0.6300
Bid0.6400 x 1800
Ask0.7400 x 1800
Day's Range0.6300 - 0.7199
52 Week Range0.6100 - 3.5900
Volume10,714
Avg. Volume77,204
Market Cap12.678M
Beta (5Y Monthly)N/A
PE Ratio (TTM)N/A
EPS (TTM)-0.3560
Earnings DateN/A
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target EstN/A
  • Simply Wall St.

    Bluejay Diagnostics, Inc. (NASDAQ:BJDX) drops to US$14m and insiders who purchased earlier this year lose another US$65k

    Insiders who acquired US$183k worth of Bluejay Diagnostics, Inc.'s ( NASDAQ:BJDX ) stock at an average price of US$1.09...

  • GlobeNewswire

    Bluejay Diagnostics, Inc. Reports Third Quarter 2022 Financial Results

    ACTON, Mass., Nov. 09, 2022 (GLOBE NEWSWIRE) -- Bluejay Diagnostics, Inc. (NASDAQ: BJDX) (“Bluejay” or the “Company”), a clinical-stage medical diagnostics company developing rapid, near-patient tests using whole blood on its Symphony platform to improve patient outcomes in critical care settings, today reported its financial results for the quarter and nine months ended September 30, 2022. “The last quarter focused on increasing awareness of Bluejay’s Symphony IL-6 test by directly engaging the

  • GlobeNewswire

    Bluejay Diagnostics, Inc. to Present at the H.C. Wainwright 24th Annual Global Investment Conference

    ACTON, Mass., Aug. 30, 2022 (GLOBE NEWSWIRE) -- Bluejay Diagnostics, Inc. (NASDAQ: BJDX) (“Bluejay”, “the Company”), a medical diagnostics company focused on developing cost-effective, rapid, near-patient tests for triage and monitoring of disease progression, today announced that Neil Dey, Chief Executive Officer, and Kenneth Fisher, Chief Financial Officer, will present at the H.C. Wainwright 24th Annual Global Investment Conference taking place on September 12-14, 2022, at the Lotte Palace Ho

Advertisement
Advertisement